About Nephrosant
Nephrosant is a company based in San Francisco (United States) founded in 2017 by Minnie Sarwal and Joshua Young Yang. Nephrosant has raised $16 million across 1 funding round from investors including DaVita Venture Group and DigitalDX Ventures. The company has 49 employees as of December 31, 2021. Nephrosant operates in a competitive market with competitors including Oxford Immunotec, Immucor, Verici Dx, Olaris and Transplant Genomics, among others.
- Headquarter San Francisco, United States
- Employees 49 as on 31 Dec, 2021
- Founders Minnie Sarwal, Joshua Young Yang
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Nephrosant, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$16 M (USD)
in 1 rounds
-
Latest Funding Round
$16 M (USD), Series A
Mar 16, 2021
-
Investors
DaVita Venture Group
& 1 more
-
Employee Count
49
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of Nephrosant
Nephrosant has successfully raised a total of $16M through 1 strategic funding round. The most recent funding activity was a Series A round of $16 million completed in March 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Nephrosant
Nephrosant has secured backing from 2 investors, including venture fund investors. Prominent investors backing the company include DaVita Venture Group and DigitalDX Ventures.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in healthcare sectors
|
Locked | Locked | Locked | |
|
DigitalDX Ventures is focused on AI and healthcare innovation investments.
|
Locked | Locked | Locked |
Investor details for Nephrosant
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Nephrosant
Investment portfolio details for Nephrosant
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Nephrosant
Detailed financials for Nephrosant
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Nephrosant Comparisons
Peer comparison for Nephrosant
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Nephrosant
Nephrosant operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Oxford Immunotec, Immucor, Verici Dx, Olaris and Transplant Genomics, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Immune markers are utilized by Oxford Immunotec for disease diagnostics.
|
|
| Locked | Locked | Locked |
Transfusion and transplantation diagnostic products are provided by Immucor.
|
|
| Locked | Locked | Locked |
Developer of diagnostic solutions for organ transplants
|
|
| Locked | Locked | Locked |
In-vitro diagnostics are developed for oncology, transplants, and neurodegeneration.
|
|
| Locked | Locked | Locked |
Molecular diagnostic tests for early graft injury detection are developed.
|
Detailed competitors of Nephrosant
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Nephrosant
Complete news archive for Nephrosant
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Nephrosant
Nephrosant was founded in 2017 and raised its 1st funding round 4 years after it was founded.
Nephrosant is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Minnie Sarwal is the current CEO of Nephrosant. They have also founded this company.
Nephrosant is a funded company, having raised a total of $16M across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Nephrosant is 49.
Nephrosant was founded in 2017 in San Francisco, United States, within the biotechnology sector. Diagnostic tools for kidney disorders are created by the company, with operations centered on early detection of transplant rejection. The primary product, QiSant, is utilized to produce a quantitative Q-Score that assesses rejection risk. Leadership is provided by co-founders Minnie Sarwal, serving as CEO, and Joshua Young Yang. The domain nephrosant.com supports these activities.
Nephrosant's top competitors include Olaris, Oxford Immunotec and Verici Dx.
Nephrosant has 2 investors. Key investors include DaVita Venture Group, and DigitalDX Ventures.